Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13250005 | 0.93 | PARP1 (0.42) | PARP1TNKS2PARP2P2RX3MAPK1 | |
| SCHEMBL13250004 | 0.90 | PARP1 (0.44) | PARP1TNKS2PARP2P2RX3MAPK1 | |
| SCHEMBL13250092 | 0.88 | PARP1 (0.44) | PARP1TNKS2PARP2P2RX3MAPK1 | |
| SCHEMBL13250194 | 0.83 | PARP1 (0.42) | PARP1TNKS2PARP2P2RX3MAPK1 | |
| SCHEMBL13328873 | 0.83 | MAPT (0.40) | PARP1TNKS2PARP2MAPK1PTGER4 | |
| SCHEMBL13249769 | 0.83 | PARP1 (0.48) | PARP1TNKS2PARP2P2RX3MAPK1 | |
| SCHEMBL13249990 | 0.82 | PARP1 (0.43) | PARP1TNKS2PARP2P2RX3MAPT | |
| SCHEMBL13250018 | 0.81 | PARP1 (0.46) | PARP1TNKS2PARP2P2RX3MKNK1 | |
| SCHEMBL13250064 | 0.81 | PARP1 (0.44) | PARP1TNKS2PARP2P2RX3MAPK1 | |
| SCHEMBL13250072 | 0.81 | PARP1 (0.44) | PARP1TNKS2PARP2P2RX3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | PARP1 995/4885TNKS2 2045/4885PARP2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.